Development of Film Dosage Forms Containing Miconazole for the Treatment of Oral Candidiasis


Film dosage forms (FDs) containing miconazole (MCZ) for the treatment of oral candidiasis were prepared using water-soluble polysaccharides, and the dissolution profiles of MCZ from the FDs were investigated. In addition, the forms were modified by the addition of a surface active agent to accelerate the drug dissolution rate. Circular films incorporating MCZ were obtained using each polysaccharide. Most FDs were easy to handle and resistant to tearing. No diffraction peaks were observed in the X-ray diffractograms of FDs. FDs prepared with sodium alginate or pullulan immediately swelled and disintegrated in aqueous medium, whereas MCZ incorporated in the FD gradually dissolved. A marked acceleration in the MCZ dissolution rate was observed when FD was prepared with polysaccharide containing a surfactant. These results confirmed that modified FDs are useful for treating localized conditions in the oral cavity, such as oral candidiasis, and that FDs can simplify the administration of drugs to patients.

Share and Cite:

Y. Murata, T. Isobe, K. Kofuji, N. Nishida and R. Kamaguchi, "Development of Film Dosage Forms Containing Miconazole for the Treatment of Oral Candidiasis," Pharmacology & Pharmacy, Vol. 4 No. 3, 2013, pp. 325-330. doi: 10.4236/pp.2013.43047.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] V. Garsuch and J. Breitkreutz, “Comparative Investigations on Different Polymers for the Preparation of FastDissolving Oral Films,” Journal of Pharmacy and Pharmacology, Vol. 62, No. 4, 2010, pp. 539-545.
[2] T. Nagaraju, R. Gowthami, M. Rajashekar, S. Sandeep, M. Mallesham, D. Sathish and Y. S. Kumar, “Comprehensive Review on Oral Disintegrating Films,” Current Drug Delivery, Vol. 10, No. 1, 2013, pp. 96-108. doi:10.2174/1567201811310010016
[3] K. B. Liew, Y. T. Tan and K. K. Peh, “Effect of Polymer, Plasticizer and Filler on Orally Disintegrating Film,” Drug Development and Industrial Pharmacy, Posted Online, 2013.
[4] Y. Murata, T. Isobe, K. Kofuji, N. Nishida and R. Kamaguchi, “Preparation of Fast Dissolving Films for Oral Dosage from Natural Polysaccharides,” Materials, Vol. 3, No. 8, 2010, pp. 4291-4299. doi:10.3390/ma3084291
[5] Y. Murata, K. Kofuji, N. Nishida and R. Kamaguchi, “Development of Film Dosage Form Containing Allopurinol for Prevention of Oral Mucositis,” International Scholarly Research Network Pharmaceutics, 2012, 5 p, Article ID: 764510. doi:10.5402/2012/764510
[6] P. Siukosaari, S. Ajwani, A. Ainamo, J. Wolf and T. Närhi, “Periodontal Health Status in the Elderly with Different Levels of Education: A 5-Year Follow-Up Study,” Gerodontology, Vol. 29, No. 2, 2012, pp. 170-178. doi:10.1111/j.1741-2358.2010.00437.x
[7] S. Offenbacher, S. P. Barros, S. Altarawneh, J. D. Beck and Z. G. Loewy, “Impact of Tooth Loss on Oral and Systemic Health,” General Dentistry, Vol. 60, No. 6, 2012, pp. 494-500.
[8] P. A. Krishnan, “Fungal Infections of the Oral Mucosa,” Indian Journal Dental Research, Vol. 23, No. 5, 2012, pp. 650-659. doi:10.4103/0970-9290.107384
[9] N. Isham and M. A. Ghannoum, “Antifungal Activity of Miconazole against Recent Candida Strains,” Mycoses, Vol. 53, No. 5, 2010, pp. 434-437. doi:10.1111/j.1439-0507.2009.01728.x
[10] C. D. Collins, S. Cookinham and J. Smith, “Management of Oropharyngeal Candidiasis with Localized Oral Miconazole Therapy: Efficacy, Safety, and Patient Acceptability,” Patient Preference and Adherence, Vol. 5, 2011, pp. 369-374. doi:10.2147/PPA.S14047
[11] J. Gronlund, T. I. Saari, N. Hagelberg, P. J. Neuvonen, K. T. Olkkola and K. Laine, “Miconazole Oral Gel Increases Exposure to Oral Oxycodone by Inhibition of CYP2D6 and CYP3A4,” Antimicrobial Agents and Chemotherapy, Vol. 55, No. 3, 2011, pp. 1063-1067. doi:10.1128/AAC.01242-10
[12] R. J. Bensadoun, J. Daoud, B. E. Gueddari, L. Bastit, R. Gourmet, A. Rosikon, C. Allavena, P. Ceruse, G. Calais and P. Attali, “Comparison of the Efficacy and Safety of Miconazole 50 mg Mucoadhesive Buccal Tablets with Miconazole 500 mg Gel in the Treatment of Oropharyngeal Candidiasis,” Cancer, Vol. 112, No. 1, 2008, pp. 204211. doi:10.1002/cncr.23152
[13] A. Madgulkar, S. Kadam and V. Pokharkar, “Development of Buccal Adhesive Tablet with Prolonged Antifungal Activity: Optimization and ex Vivo Deposition Studies,” Indian Journal Pharmaceutical Sciences, Vol. 71, No. 3, 2009, pp. 290-294.
[14] M. R. Bhalekar, V. Pokharkar, A. Madgulkar, N. Patil and N. Patil, “Preparation and Evaluation of Miconazole Nitrate-Loaded Solid Liquid Nanoparticles for Topical Delivery,” American Association of Pharmaceutical Scientists PharmSciTech, Vol. 10, No. 1, 2009, pp. 289-296.
[15] L. K. Pershing, J. Corlett and C. Jorgensen, “In Vivo Pharmacokinetics and Pharmacodynamics of Topical Ketoconazole and Miconazole in Human Stratum Corneum,” Antimicrobial Agents and Chemotherapy, Vol. 38, No. 1, 1994, pp. 90-95. doi:10.1128/AAC.38.1.90
[16] B. Nauntofte, J. O. Tenovuo and F. Lagerlof, “Secretion and Composition of Saliva,” In: O. Fejerskov and E. A. M. Kidd, Eds., Dental Caries the Disease and Its Clinical Management, Blackwell Munksgaad, Oxford, 2003, pp. 7-27.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.